The low dosage might be a key reason why CureVac's (5CV.DE) COVID-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday.
Peter Kremsner from the University Hospital in Tuebingen which is running the trial told Reuters the low efficacy is "very likely due to the dose".
With just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively. However, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar. The news wiped as much as 52% off the company's value on Thursday.CureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How a low-profile Senate vote could spell trouble for Big TechThe senate confirmed Lina Khan, an established critic of tech companies' market power, to a seat on the Federal Trade Commission by a 69-28 margin, picking up support from a bipartisan coalition favoring more aggressive action against Big Tech.
Read more »
Leslie Grace’s Guide to Low-Key Glam Makeup and Second-Day BlowoutsWatch IntheHeights star Leslie Grace reveal her BeautySecrets, from false eyelashes to how she prolongs the lifespan of her blowout.
Read more »
CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effectiveThe late-stage clinical trial found high prevalence of virus variants.
Read more »
CureVac says its COVID vaccine was poor match against 29 COVID variants, as global case tally tops 177 millionThe global tally of confirmed cases of COVID-19 climbed above 177 million on Thursday, a day after disappointing news from CureVac with the German company...
Read more »
CureVac’s pain may not yet have peakedCureVac’s , (5CV.DE) vaccine agony may have further to run. The German biotechnology company’s Frankfurt-listed shares halved on Thursday after the group revealed that its Covid-19 jab may be only 47% effective. That’s a major blow, but the bigger concern for investors is if CureVac’s so-called “messenger RNA” technology behind its cancer and rabies vaccines has flaws.
Read more »
Africa's Covid patients 'dying from lack of oxygen'Health agencies and medics tells the BBC of a growing crisis facing low-income African nations.
Read more »